- Home
- KFS vs PRTA Comparison
KFS vs PRTA Comparison
Compare KFS & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KFS
- PRTA
- Stock Information
- Founded
- KFS 1989
- PRTA 2012
- Country
- KFS United States
- PRTA Ireland
- Employees
- KFS N/A
- PRTA N/A
- Industry
- KFS Property-Casualty Insurers
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- KFS Finance
- PRTA Health Care
- Exchange
- KFS Nasdaq
- PRTA Nasdaq
- Market Cap
- KFS 417.8M
- PRTA 472.1M
- IPO Year
- KFS 1996
- PRTA N/A
- Fundamental
- Price
- KFS $14.37
- PRTA $8.20
- Analyst Decision
- KFS
- PRTA Buy
- Analyst Count
- KFS 0
- PRTA 10
- Target Price
- KFS N/A
- PRTA $14.86
- AVG Volume (30 Days)
- KFS 69.0K
- PRTA 1.2M
- Earning Date
- KFS 08-07-2025
- PRTA 08-04-2025
- Dividend Yield
- KFS N/A
- PRTA N/A
- EPS Growth
- KFS N/A
- PRTA N/A
- EPS
- KFS N/A
- PRTA N/A
- Revenue
- KFS $119,287,000.00
- PRTA $10,341,000.00
- Revenue This Year
- KFS N/A
- PRTA N/A
- Revenue Next Year
- KFS N/A
- PRTA $389.77
- P/E Ratio
- KFS N/A
- PRTA N/A
- Revenue Growth
- KFS 12.05
- PRTA N/A
- 52 Week Low
- KFS $7.06
- PRTA $4.32
- 52 Week High
- KFS $16.80
- PRTA $22.83
- Technical
- Relative Strength Index (RSI)
- KFS 54.71
- PRTA 58.73
- Support Level
- KFS $13.96
- PRTA $8.05
- Resistance Level
- KFS $14.36
- PRTA $8.73
- Average True Range (ATR)
- KFS 0.38
- PRTA 0.38
- MACD
- KFS 0.05
- PRTA -0.05
- Stochastic Oscillator
- KFS 89.60
- PRTA 47.62
About KFS Kingsway Financial Services Inc. (DE)
Kingsway Financial Services Inc through subsidiaries operates in the extended warranty and business services industries in the United States. The company operates through segments namely, Extended Warranty and Kingsway Search Xcelerator. The Extended Warranty segment provides after-market vehicle protection services distributed by credit unions. The firm generates maximum revenue from the Extended Warranty segment in the form of Service fee and commission income.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.